Atlas Trials

Value of SGLT2 Inhibitor (Dapagliflozin) as an Added Therapy in Diabetic Patients With Heart Failure With Reduced Ejection Fraction; Randomized Controlled Clinical Trial

Clinical trial NCT04304560 · UNKNOWN

Trial details

NCT number
NCT04304560
Sponsor
Damanhour University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Heart Failure With Reduced Ejection Fraction (HFrEF)Diabete Type 2Cardiomyopathies
Start date
2020-03-01
Primary completion
2021-03-01
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.